References: Hair growth and hair loss
J Clin Oncol. 1985 Nov;3(11):1471-7.
VP-16 and cisplatin as first-line therapy for small-cell lung cancer.
Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G.
Thirty-one patients with small-cell lung cancer (SCLC) were treated with VP-16 and cisplatin as first-line therapy. In the majority of cases an Adriamycin (Adria Laboratories, Columbus, Ohio) containing regimen was contraindicated because of severe cardiac or hepatic disease. Eight patients who presented with cerebral metastases were also included in the series. Eleven patients had limited disease (LD), and 20 had extensive disease (ED). Of the 28 evaluable patients, 12 (43%) achieved a complete response (CR) and 12 (43%) had a partial response (PR). Four patients (14%) either had no response or progressed on treatment. The median duration of response for patients with LD was 39 weeks and for those with ED, 26 weeks. The median survival time (MST) for the whole group of responding (CR and PR) LD patients was 70 weeks (range, 28 to 181 + weeks), and for responding ED patients, it was 43 weeks (range, 17 to 68 weeks). Gastrointestinal toxicity was mild, but leukopenia and thrombocytopenia were common. There were four febrile episodes during periods of drug-induced neutropenia and this led to one treatment-related death. Nephrotoxicity occurred in 15 patients and required discontinuation of cisplatin in two. These results compare favorably with reports of standard induction chemotherapy regimens and provide further evidence of the activity of the VP-16 and cisplatin regimen in patients with SCLC.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2997406&dopt=Abstract
Gan To Kagaku Ryoho. 1985 Dec;12(12):2352-7.
[A phase II study of etoposide (NK 171) in small cell lung cancer--comparison of results between intravenous administration and oral administration]
[Article in Japanese]
Furuse K.
A phase II study of Etoposide (NK 171) was carried out in 13 institutions of the National Chest Hospital Lung Cancer Cooperative Study Group. Twenty-two patients (pts.) were treated by intravenous (i.v.) administration of etoposide, 80 mg/m2/day, for 5 consecutive days, and 25 pts. by oral administration of the same drug, 130 mg/m2/day, for 5 consecutive days. Eight (36.4%) out of 22 evaluable pts. given i.v. etoposide showed partial response (PR) while 7 (28%) out of 25 evaluable pts. given oral etoposide showed PR. Thirteen (41%) out of 32 previously untreated pts. were responders, but only 2 (13%) out of 15 previously treated pts. responded. The average total dose of i.v. etoposide was 664 (368-1552) mg/m2 while that of oral etoposide was 1320 mg/m2, or about double the dose of i.v. etoposide. The major dose-limiting factor was leukopenia (less than 3000/mm3). being observed in 63.6% of the i.v. treated pts. and 31.8% of the orally-treated pts. The oral and i.v. etoposide provided equivalent results. Despite the advantage of the reduced myelotoxicity of oral etoposide, we may recommend that all pts. are treated parenterally at present until the problem of erratic absorption of the oral drug is resolved.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3000299&dopt=Abstract
Gan To Kagaku Ryoho. 1986 Jan;13(1):116-21.
[A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group]
[Article in Japanese]
Kado M, Oshima S, Matsui Y, Shimokata K, Hara K, Kanda T, Shima K, Takenaka S.
A Phase II Study of VP-16 was performed in 58 patients with primary lung cancer. VP-16 was administered via infusion at a dosage of 60-100 mg/m2 daily for 5 days, and repeated every 3 to 4 weeks. Of the 58 patients who entered into the study, 38 were evaluable. Partial response was observed in 6 patients who had been diagnosed as having small cell carcinoma of the lung. Response rates were 15.8% for all evaluated patients and 33.3% for the patients with small cell carcinoma of the lung. As for dose-limiting toxicity, leukopenia (less than 3,000/mm3) was observed in 53.1% of cases. Other major adverse reactions were hematologic toxicities such as anemia and thrombocytopenia, gastrointestinal toxicities and alopecia, but these were all well tolerated.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3002282&dopt=Abstract
Natural Herbal Supplements ||
Hair Million herbal formula for hair loss and hair growth ||
Hair growth research references ||
Online Pharmacy : discount prescription medication ||